Dermatomyositis and polymyositis are the idiopathic inflammatory myopathies of autoimmune origin. Apart from muscle weakness, general symptoms such as the affection of visceral organs and altered indicators of humeral immunity occur in a minority of patients. The aim of the study was to establish whether the systemic manifestations of the disease, altered immunoserologic parameters and findings of muscle vasculitis occurred more frequently in patients with dermatomyositis or polymyositis. The frequency of clinic, serologic and histopathologic alterations in the groups of patients with dermatomyositis and polymyositis was determined. In order to determine the degree and importance of the frequency, the following parameters were calculated: the relative rations of frequencies and the importance of the difference in frequencies of particular alterations between the groups of patients. It was found that extramuscular manifestations of the disease such as arthritis, pulmonary, cardiac and renal changes, the increased activity of C3 and C4 complement components as well as vasculitis of muscle and skin tissue occurred more frequently in patients with dermatomyositis. This finding indicates that patients with DM, regardless of the degree of muscular affection, may have a more severe clinical course of the disease and a poor prognosis.

Download full-text PDF

Source

Publication Analysis

Top Keywords

dermatomyositis polymyositis
12
patients dermatomyositis
12
idiopathic inflammatory
8
manifestations disease
8
occurred frequently
8
frequently patients
8
alterations groups
8
groups patients
8
patients
6
[systemic manifestations
4

Similar Publications

Background And Aims: Several systemic autoimmune diseases predispose to the enhancement of Atherosclerotic Cardiovascular Disease (ASCVD). These findings underline the role of inflammation in atherogenesis. Dermatomyositis (DM) and polymyositis (PM) are polygenic autoimmune disorders involving mainly skeletal muscles.

View Article and Find Full Text PDF

Troponin is a highly specific biomarker for myocardial injury. It plays a critical role in the diagnosis of acute coronary syndrome (ACS). However, elevated troponin levels are not exclusively due to cardiac ischemia and may be observed in many non-cardiac conditions, including inflammatory myopathies.

View Article and Find Full Text PDF

Safety and Efficacy of Long-term Use of Infliximab in Severe Juvenile Dermatomyositis - 12 Years of Follow-up.

Acta Dermatovenerol Croat

November 2024

Prof. Marija Jelušić, MD, PhD, Department of Paediatrics, University of Zagreb, School of Medicine, Division of Clinical Immunology, Rheumatology and Allergology, Centre of Reference for Paediatric and Adolescent Rheumatology of Ministry of Health of the Republic Croatia, University Hospital Centre Zagreb, Kispaticeva 12, 10 000 Zagreb, Croatia;

Juvenile dermatomyositis with emphasized vasculopathy is rare, but the most severe form of the disease, with a poor prognosis with relapsing and chronic course or, in some cases, lethal outcome. We present a case of a 19-year-old Caucasian female, who developed severe acute juvenile dermatomyositis with emphasized multisystem vasculopathy, including retinal vasculopathy and maculopathy (cotton-wool spots, retinal hemorrhages, macular edema) at the age of 8. Due to no response to standard treatment protocols and rapid worsening of clinical symptoms and laboratory findings, a TNF inhibitor (infliximab) was introduced after the third week of treatment resulting in complete normalisation of muscle enzyme levels and complete resolution of eye changes within the next 2 weeks with a gradual general recovery.

View Article and Find Full Text PDF

Background: Dermatomyositis is a chronic autoimmune disease with distinctive cutaneous eruptions and muscle weakness, and the pathophysiology is characterised by type I interferon (IFN) dysregulation. This study aims to assess the efficacy, safety, and target engagement of dazukibart, a potent, selective, humanised IgG1 neutralising monoclonal antibody directed against IFNβ, in adults with moderate-to-severe dermatomyositis.

Methods: This multicentre, double-blind, randomised, placebo-controlled, phase 2 trial was conducted at 25 university-based hospitals and outpatient sites in Germany, Hungary, Poland, Spain, and the USA.

View Article and Find Full Text PDF

Objective: To evaluate the main outcomes of disease activity and their association with other measures of activity, damage, and quality of life in patients with idiopathic inflammatory myopathy (IIM) according to time since diagnosis and positivity to antisynthetase autoantibodies (ASAs).

Methods: Cross-sectional multicenter study within the Spanish Myo-Spain registry. Cases were classified as incident (≤ 12 months since diagnosis) and prevalent.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!